Anticancer activity application of chiral bisoxazoline copper complex

By preparing chiral bisoxazoline copper complex, the problem that the medical use and anti-cancer activity of such substances in the prior art has been solved, and the significance in lung, liver, breast, and colon cancer cells has been achieved. Inhibiting activity, simple process and high yield.

CN118955416APending Publication Date: 2024-11-15HEFEI UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411031867.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, the medical use of chiral bisoxazoline copper complexes has few reports, and their anti-cancer activity has not been fully studied.

Method used

By using o-hydroxyoxazoline as ligand, chiral bisoxazoline copper complex was prepared, and the high-temperature reflux and column chromatography separation process was used to obtain single crystals of complexes of two configurations, and their anti-cancer activity was performed. Preliminary study.

Benefits of technology

This chiral bioxazoline copper complex showed significant inhibitory activity in lung, liver, breast and colon cancer cell experiments, with high yield, simple process and convenient operation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955416A_ABST
    Figure CN118955416A_ABST
Patent Text Reader

Abstract

The invention relates to an application of a bis {2-[4 (R +)-phenyl-4, 5-dihydro]-2-oxazolinyl} phenol copper complex I which is shown in the following chemical formula and has unit cell parameters: the crystal I copper complex respectively shows certain inhibitory activity in anti-cancer cell tests, such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480, and the inhibition ratios of the crystal I copper complex are respectively 3.263 + / -0.09, 5.767 + / -0.013, 3.044 + / -0.089 and 17.23 + / -0.89; and the sizes of the crystals II are 6.405 + / -0.091, 6.206 + / -0.231, 1.355 + / -0.075 and 4.835 + / -0.287 respectively. The compound shows certain inhibitory activity in anti-cancer cell tests such as lung cancer A-549, and the anti-cancer inhibition rate of the compound is 8.58 + / -2.27; chemical formula of crystal complex I is as follows: # imgabs 0 #, and chemical formula of crystal complex II is as follows: # imgabs 1 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an anticancer use of a metal organic coordination compound (complex), in particular to an anticancer use of a nitrogen-containing oxazoline metal organic complex, more specifically to an anticancer use of a chiral bis-oxazoline copper complex. Background Art

[0002] With the development of organic chemistry, the application of metal organic compounds in organic synthesis is becoming more and more extensive. It is one of the most active fields in organic chemistry and has been widely used in organic synthesis reactions. The emergence of asymmetric synthesis reactions catalyzed by chiral ligands and transition metal complexes in the late 1960s greatly accelerated the research on chiral drugs. In recent years, chiral bisoxazoline ligand-copper metal complexes have made certain progress in the field of anticancer drug chemistry research. [1-2]

[0003] References:

[0004] 1.Ma,WB;Wemg,ZY;Rogge,T.;Gu,LH;Lin,JF;Peng,A.;Luo,X.;GouX.J.Adv.Syn.Cat.,2018,360(4),704-710.

[0005] 2. Luo Mei, Li Guoxiong, Xie Lan, Chinese patent: application number: 201910988370.3. Summary of the invention

[0006] The present invention aims to provide a Cu-N metal organic complex for application in the field of medicine. The technical problem to be solved is to select o-hydroxyoxazoline as a ligand and study the anticancer use of the copper complex of chiral bisoxazoline. The inventor applied for two Chinese invention patents related to this patent in 2013: the application numbers are 201310305287.4; 201310474961.1; the invention names are: a method for synthesizing a chiral bisoxazoline copper complex crystal; a chiral oxazoline copper complex and its synthesis method. However, there are very few reports on the medical use of the complex. At present, the applicant has re-synthesized the reported complex in the study of the anticancer activity of the complex, and obtained two configurations of the complex single crystals. After re-testing, a preliminary study of the use was conducted and it was found that it has anticancer activity.

[0007] The chiral bis-oxazoline copper complex referred to in the present invention is a complex prepared from o-hydroxybenzonitrile, D-phenylglycinol and copper acetate monohydrate and represented by the following chemical formula:

[0008]

[0009] Chemical name: bis{2-[4(R-(+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex, referred to as complex (I).

[0010] The synthesis method of the complex is as follows: add 0.9938g (4.98mmol) of copper acetate monohydrate, 50mL of chlorobenzene, 1.0551g (5.28mmol) of o-hydroxybenzonitrile, and 3.9240g of D-phenylglycinol into a 100mL two-necked bottle, reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and naturally volatilize the last component to obtain a single crystal of the complex. The synthesis reaction is as follows:

[0011]

[0012] The chiral copper complex of bisoxazoline referred to in the present invention is a complex prepared from o-hydroxybenzonitrile, L-phenylglycinol and copper acetate monohydrate and represented by the following chemical formula:

[0013]

[0014] The synthesis method of the complex is as follows: 1.7923 g of copper acetate monohydrate, 50 mL of chlorobenzene, 1.7966 g of o-hydroxybenzonitrile, and 3.97686 g of L-phenylglycinol are added to a 100 mL two-necked bottle, the mixture is refluxed at high temperature for 72 hours, the reaction is stopped, the mixture is washed with petroleum ether and dichloromethane, column chromatography is performed for separation, and the last component is naturally volatilized to obtain a single crystal of the complex;

[0015] The synthetic reaction is as follows:

[0016]

[0017] The synthetic method can obtain the target product in one step, and the process is simple and the operation is convenient. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 X-ray diffraction analysis of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex.

[0019] Figure 2 X-ray diffraction analysis of bis{2-[4(S-(-)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex.

[0020] In the preparation and characterization part, due to the re-measurement of the unit cell parameters of the copper complex of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol α=90°; β=99.2350(10)°;

[0021] γ=90° is basically the same as the unit cell parameters provided in the 2013 Chinese invention patent 201310305287.4: a=10.0458(7)A alpha=90deg.b=22.9702(4)A beta=99.848(2)deg.c=11.1154(8)A gamma=90deg. The inventor re-tested the infrared data part. DETAILED DESCRIPTION

[0022] 1. Preparation of bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex

[0023] In a 100mL two-necked bottle, add 0.9938g (25.7mmol) of copper acetate monohydrate, 50mL of chlorobenzene, 1.1709g of o-hydroxybenzonitrile, and 3.9240g of D-phenylglycinol. Reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and evaporate the last component naturally to obtain a single crystal of the complex. Yield: 70%, mp:>200℃, [a] 5 D =+274.4°(c=1.036,CH2Cl2), elemental analysis: tested value: C: 66.22%, H: 4.39%, N: 5.26%; calculated value: 66.72%, 4.48%, N, 5.19%; IR(KBr): 3439, 2919, 1618, 1543, 1472, 1447, 1392, 1342,1266, 1154, 1082, 937, 853, 760, 700; MS(ESI): m-1 / z(%): calcd for C30H24N2O4Cu: 539.0780; found: 540.0264.

[0024] The crystal data of the complex are as follows:

[0025]

[0026]

[0027] Typical bond length data for crystals:

[0028]

[0029]

[0030]

[0031]

[0032]

[0033] Typical bond angle data of crystals:

[0034]

[0035]

[0036]

[0037]

[0038]

[0039]

[0040]

[0041] 2. Preparation of bis{2-[4(S-(-)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex

[0042] In a 100mL two-necked bottle, add 1.0478g of copper acetate monohydrate, 50mL of chlorobenzene, 1.1709g of o-hydroxybenzonitrile, and 4.0516g of L-phenylglycinol. Reflux the mixture at high temperature for 72h, stop the reaction, elute with petroleum ether and dichloromethane, separate by column chromatography, and evaporate the last component naturally to obtain a single crystal of the complex. The yield is 76%, mp:>200℃, [a] 5 D =-201.5°(c=0.034,CH2Cl2), elemental analysis: calculated value: C: 66.72%, H: 4.48%, N: 5.19%; found value: C: 66.61%, H: 4.43%, N: 5.27%; IR: 3439, 2919, 1618, 1543, 1472, 1447, 1392, 1344, 1266, 1239, 1154, 1082, 937, 853, 760, 664, 569, 537; MS (ESI): m-1 / z(%): calcd for C30H24N2O4Cu: 539.0780; found: 540.0186.

[0043] The crystal data of the complex are as follows:

[0044]

[0045]

[0046] Table 3 Typical bond length data of Crystal II:

[0047]

[0048]

[0049]

[0050]

[0051]

[0052] Table 4 Typical bond angle data of crystals

[0053]

[0054]

[0055]

[0056]

[0057]

[0058]

[0059]

[0060] 4. Anticancer activity application

[0061] The organic complex crystals I and II synthesized according to the structural design of the active natural product in the present invention both show certain inhibitory activity in anticancer cell tests such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480. The inhibition rates of crystal I are 3.263±0.09, 5.767±0.013, 3.044±0.089 and 17.23±0.89; and crystal II are 6.405±0.091, 6.206±0.231, 1.355±0.075 and 4.835±0.287.

[0062] Table 5. Anticancer experimental results

[0063]

[0064] The specific results of the anticancer activity test of the chiral organic complex crystals 1 and 2 are shown in the table above.

Claims

1. A use of a bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex I shown by the following chemical formula and unit cell parameters: the crystal I copper complex shows certain inhibitory activity in anticancer cell tests such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480, and the inhibition rates are 3.263±0.09, 5.767±0.013, 3.044±0.089 and 17.23±0.89 respectively; the crystal II is 6.405±0.091, 6.206±0.231, 1.355±0.075 and 4.835±0.287; in anticancer cell tests such as lung cancer A-549, the crystal II shows certain inhibitory activity, and the anticancer inhibition rate is 8.58±2.27; The chemical formula of the complex is as follows: Its unit cell parameters are as follows: monoclinic system, P1 21 1; its unit cell parameters: α=90°; β=99.2350(10)°; γ=90°.

2. A use of a bis{2-[4(R+)-phenyl-4,5-dihydro]-2-oxazolinyl}phenol copper complex II represented by the following chemical formula and unit cell parameters: the crystal II copper complex shows certain inhibitory activity in anticancer cell tests such as lung cancer A-549, liver cancer SMMC-7721, breast cancer MDA-MB-231 and colon cancer SW480, and its anticancer inhibition rates are 6.405±0.091, 6.206±0.231, 1.355±0.075 and 4.835±0.287, respectively. Its unit cell parameters are as follows: monoclinic system, P1 21 1, unit cell parameters: α=90°; β=99.1460(10)°; γ=90°.